Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation
Anna C Renner1, Robert B Kargbo2
1North Dakota State University, Fargo, North Dakota 58108-6050, United States.
None:
Recent patent disclosures from Gilead Sciences reveal a coordinated, multimodal strategy to control STAT6 signaling therapeutically. Small-molecule modulators provide tunable, tissue-focused pathway attenuation, while heterobifunctional degraders enable more profound and potentially more durable suppression. Together, these inventions define STAT6 as a context-sensitive target whose optimal intervention depends on disease biology, exposure, and required depth of pathway control.
Related Concept Videos
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Regulation of Expression at Multiple Steps


